Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries

The 9vHPV vaccine was efficacious, immunogenic, and well-tolerated in Asian participants from 2 international, randomized clinical trials. Data support 9vHPV vaccination programs in Asia.

[1]  J. Cuzick,et al.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial , 2017, The Lancet.

[2]  Samuel Phillips,et al.  Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination , 2017, International journal of cancer.

[3]  S. Iwata,et al.  Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls. , 2017, Japanese journal of infectious diseases.

[4]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[5]  J. Cuzick,et al.  Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials , 2017, Papillomavirus research.

[6]  Anne M Johnson,et al.  Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types , 2017, Papillomavirus research.

[7]  J. Cuzick,et al.  Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials , 2016, Pediatrics.

[8]  Y. Ueda,et al.  Outcomes for girls without HPV vaccination in Japan. , 2016, The Lancet. Oncology.

[9]  F. Bray,et al.  Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. , 2016, The Lancet. Global health.

[10]  N. Muñoz,et al.  Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C. Bauch,et al.  National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States , 2016, Proceedings of the National Academy of Sciences.

[12]  E. Joura,et al.  Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria , 2016, BMC Infectious Diseases.

[13]  D. Ekwueme,et al.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model , 2016, Human vaccines & immunotherapeutics.

[14]  IPVS Policy statement on safety of HPV vaccines , 2015, Papillomavirus research.

[15]  P. Pitisuttithum,et al.  9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV , 2015, Expert review of vaccines.

[16]  N. Muñoz,et al.  Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. , 2015, European journal of cancer.

[17]  S. Kjaer,et al.  An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015 , 2015, The Pediatric infectious disease journal.

[18]  X. Castellsagué,et al.  Immunogenicity and Safety of a 9-Valent HPV Vaccine , 2015, Pediatrics.

[19]  R. Kishi,et al.  HPV vaccination crisis in Japan , 2015, The Lancet.

[20]  E. Moreira,et al.  Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine , 2015, Human vaccines & immunotherapeutics.

[21]  Joshua Chen,et al.  Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. , 2015, Contemporary clinical trials.

[22]  Kate Soldan,et al.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis , 2015, BDJ.

[23]  A. Giuliano,et al.  Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine , 2015, Human vaccines & immunotherapeutics.

[24]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[25]  R. Gesser,et al.  A seamless Phase IIB/III adaptive outcome trial: Design rationale and implementation challenges , 2015, Clinical trials.

[26]  Jack Cuzick,et al.  Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[27]  Mark Jit,et al.  Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. , 2014, The Lancet. Global health.

[28]  A. Saah,et al.  Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types , 2014, Human vaccines & immunotherapeutics.

[29]  M. Pillsbury,et al.  Projecting the Potential Public Health Impact of A 9-Valent HPV Vaccine in Japan , 2014 .

[30]  M. Jit,et al.  Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. , 2013, Vaccine.

[31]  T. Weiss,et al.  Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease , 2012, Infectious Agents and Cancer.

[32]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[33]  M. Jit,et al.  Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[34]  S. Garland,et al.  Cervical Cancer Burden and Prevention Strategies: Asia Oceania Perspective , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[35]  S. Goldie,et al.  Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden , 2011, BMC infectious diseases.

[36]  J. Bryan,et al.  Comparison of Real-Time Multiplex Human Papillomavirus (HPV) PCR Assays with the Linear Array HPV Genotyping PCR Assay and Influence of DNA Extraction Method on HPV Detection , 2011, Journal of Clinical Microbiology.

[37]  J. Bryan,et al.  Comparison of Real-Time Multiplex Human Papillomavirus (HPV) PCR Assays with INNO-LiPA HPV Genotyping Extra Assay , 2010, Journal of Clinical Microbiology.

[38]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[39]  M. Wong,et al.  Distribution of human papillomavirus types in cervical cancers in Hong Kong: Current situation and changes over the last decades , 2009, International journal of cancer.

[40]  R. Railkar,et al.  Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. , 2009, The Journal of infectious diseases.

[41]  M. Postma,et al.  Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis , 2017, Japanese journal of clinical oncology.

[42]  Hai-rim Shin,et al.  Prevention of infection-related cancers in the WHO Western Pacific Region. , 2016, Japanese journal of clinical oncology.

[43]  M. Poljak,et al.  Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide , 2015, International journal of cancer.

[44]  Global Advisory Committee on Vaccine Safety, 3–4 December 2014. , 2015, Releve epidemiologique hebdomadaire.

[45]  Who,et al.  Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[46]  I. Chan,et al.  Exact power and sample size for vaccine efficacy studies , 1998 .